Sparfloxacin

Summary

Sparfloxacin (CHEMBL850) is an approved small molecule (ATC J01MA09); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA09
• Indications: 2 conditions
• Chemistry: 392.4 Da · C19H22F2N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL850
Name	Sparfloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	60464
ChEBI	CHEBI:9212
ATC	J01MA09
Molecular formula	C19H22F2N4O3
Molecular weight	392.4
InChIKey	DZZWHBIBMUVIIW-DTORHVGOSA-N

SMILES: C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F

IUPAC name: 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid

Also known as: AT-4140, CI-978, Esparfloxacino, NSC-759641, Sparfloxacin, Sparfloxacine, Spara, Zagam, sparfloxacin, SID26719819, SID29218052, SPARFLOXACIN

Patent coverage: 5,339 distinct patent families (19,346 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 19,205 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Voltage-gated L-type calcium channel, DNA polymerase beta, Voltage-gated inwardly rectifying potassium channel KCNH2, Mitogen-activated protein kinase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	5.35	Potency	4467	nM	CHEMBL_ACT_4709727
KCNH2	5.17	AC50	6800	nM	CHEMBL_ACT_25117669

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).